Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Lucantoni

Showing results (1-10 of 17) with videos related to

Pageof 2
Sort By:
Frontiers in Cell and Developmental Biology|September 27, 2018
Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1Federico Lucantoni, Heiko Dussmann, Jochen H M Prehn
Organic & Biomolecular Chemistry|October 7, 2021
Fluorescent styrylpyrylium probes for the imaging of mitochondria in live cellsIgnacio Muñoz Resta, Federico Lucantoni, Nadezda Apostolova, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|July 2, 2021
BCL(X)L and BCL2 increase mitochondrial dynamics in breast cancer cell: Evidence from functional and genetic studiesFederico Lucantoni, Manuela Salvucci, Heiko Dussmann, et al.
Oncotarget|June 15, 2018
BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucoseFederico Lucantoni, Heiko Düssmann, Irene Llorente-Folch, et al.
Cell Death & Disease|January 21, 2018
Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cellsFederico Lucantoni, Andreas U Lindner, Norma O'Donovan, et al.
Bioconjugate Chemistry|March 31, 2025
Introducing TAPY as a Versatile Alternative to TPP for Selective Mitochondrial Targeting in Cancer CellsJean C Neto, Federico Lucantoni, Leydy V González, et al.
Cell Death and Differentiation|December 17, 2020
BCL(X)L and BCL2 increase the metabolic fitness of breast cancer cells: a single-cell imaging studyFederico Lucantoni, Manuela Salvucci, Heiko Düssmann, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|March 23, 2020
[An integral view of cancer (III). Evaluation of new biomarkers and treatment strategies]Rosa Noguera, Rebeca Burgos-Panadero, Federico Lucantoni, et al.
Cancer Letters|July 21, 2019
The tumour microenvironment as an integrated framework to understand cancer biologyRebeca Burgos-Panadero, Federico Lucantoni, Esther Gamero-Sandemetrio, et al.
Cancers|July 1, 2020
Integrating the Tumor Microenvironment into Cancer TherapySabina Sanegre, Federico Lucantoni, Rebeca Burgos-Panadero, et al.
Pageof 2

Showing results (1-10 of 17) with videos related to

Sort By:
Pageof 2
Frontiers in Cell and Developmental Biology|September 27, 2018
Metabolic Targeting of Breast Cancer Cells With the 2-Deoxy-D-Glucose and the Mitochondrial Bioenergetics Inhibitor MDIVI-1Federico Lucantoni, Heiko Dussmann, Jochen H M Prehn
Organic & Biomolecular Chemistry|October 7, 2021
Fluorescent styrylpyrylium probes for the imaging of mitochondria in live cellsIgnacio Muñoz Resta, Federico Lucantoni, Nadezda Apostolova, et al.
Biochimica Et Biophysica Acta. Molecular Cell Research|July 2, 2021
BCL(X)L and BCL2 increase mitochondrial dynamics in breast cancer cell: Evidence from functional and genetic studiesFederico Lucantoni, Manuela Salvucci, Heiko Dussmann, et al.
Oncotarget|June 15, 2018
BCL2 and BCL(X)L selective inhibitors decrease mitochondrial ATP production in breast cancer cells and are synthetically lethal when combined with 2-deoxy-D-glucoseFederico Lucantoni, Heiko Düssmann, Irene Llorente-Folch, et al.
Cell Death & Disease|January 21, 2018
Systems modeling accurately predicts responses to genotoxic agents and their synergism with BCL-2 inhibitors in triple negative breast cancer cellsFederico Lucantoni, Andreas U Lindner, Norma O'Donovan, et al.
Bioconjugate Chemistry|March 31, 2025
Introducing TAPY as a Versatile Alternative to TPP for Selective Mitochondrial Targeting in Cancer CellsJean C Neto, Federico Lucantoni, Leydy V González, et al.
Cell Death and Differentiation|December 17, 2020
BCL(X)L and BCL2 increase the metabolic fitness of breast cancer cells: a single-cell imaging studyFederico Lucantoni, Manuela Salvucci, Heiko Düssmann, et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia|March 23, 2020
[An integral view of cancer (III). Evaluation of new biomarkers and treatment strategies]Rosa Noguera, Rebeca Burgos-Panadero, Federico Lucantoni, et al.
Cancer Letters|July 21, 2019
The tumour microenvironment as an integrated framework to understand cancer biologyRebeca Burgos-Panadero, Federico Lucantoni, Esther Gamero-Sandemetrio, et al.
Cancers|July 1, 2020
Integrating the Tumor Microenvironment into Cancer TherapySabina Sanegre, Federico Lucantoni, Rebeca Burgos-Panadero, et al.
Pageof 2